These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 28612257)

  • 21. Prospective study on cytokine levels in medication-naïve adolescents with first-episode major depressive disorder.
    Lee H; Song M; Lee J; Kim JB; Lee MS
    J Affect Disord; 2020 Apr; 266():57-62. PubMed ID: 32056928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis.
    Çakici N; Sutterland AL; Penninx BWJH; Dalm VA; de Haan L; van Beveren NJM
    Brain Behav Immun; 2020 Aug; 88():547-558. PubMed ID: 32330592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher baseline interleukin-1β and TNF-α hamper antidepressant response in major depressive disorder.
    Benedetti F; Poletti S; Vai B; Mazza MG; Lorenzi C; Brioschi S; Aggio V; Branchi I; Colombo C; Furlan R; Zanardi R
    Eur Neuropsychopharmacol; 2021 Jan; 42():35-44. PubMed ID: 33191075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.
    Goldsmith DR; Rapaport MH; Miller BJ
    Mol Psychiatry; 2016 Dec; 21(12):1696-1709. PubMed ID: 26903267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis.
    García-García ML; Tovilla-Zárate CA; Villar-Soto M; Juárez-Rojop IE; González-Castro TB; Genis-Mendoza AD; Ramos-Méndez MÁ; López-Nárvaez ML; Saucedo-Osti AS; Ruiz-Quiñones JA; Martinez-Magaña JJ
    Psychiatry Res; 2022 Jan; 307():114317. PubMed ID: 34864233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery.
    Dahl J; Ormstad H; Aass HC; Malt UF; Bendz LT; Sandvik L; Brundin L; Andreassen OA
    Psychoneuroendocrinology; 2014 Jul; 45():77-86. PubMed ID: 24845179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in peripheral blood compounds following psychopharmacological treatment in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis.
    Çakici N; Sutterland AL; Penninx BWJH; de Haan L; van Beveren NJM
    Psychol Med; 2021 Mar; 51(4):538-549. PubMed ID: 33653423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory Biomarker and Response to Antidepressant in Major Depressive Disorder: a Systematic Review and Meta-Analysis.
    Gasparini A; Callegari C; Lucca G; Bellini A; Caselli I; Ielmini M
    Psychopharmacol Bull; 2022 Feb; 52(1):36-52. PubMed ID: 35342200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of inflammatory cytokines in drug-naïve major depressive disorder: A systematic review and meta-analysis.
    Islam MR; Sohan M; Daria S; Masud AA; Ahmed MU; Roy A; Shahriar M
    Int J Immunopathol Pharmacol; 2023; 37():3946320231198828. PubMed ID: 37625799
    [No Abstract]   [Full Text] [Related]  

  • 30. The relationship between serum resolvin D1, NLRP3, cytokine levels, and adolescents with first-episode medication-naïve major depressive disorder.
    Guo J; Zhang T; Chen W; Tan J; Li X; Zheng A; Fu Y; Qiu T
    BMC Psychiatry; 2024 Apr; 24(1):285. PubMed ID: 38627683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis.
    Bavaresco DV; Uggioni MLR; Ferraz SD; Marques RMM; Simon CS; Dagostin VS; Grande AJ; da Rosa MI
    Pharmacol Biochem Behav; 2020 Jan; 188():172838. PubMed ID: 31837338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression.
    Schmidt FM; Schröder T; Kirkby KC; Sander C; Suslow T; Holdt LM; Teupser D; Hegerl U; Himmerich H
    Psychiatry Res; 2016 May; 239():85-91. PubMed ID: 27137966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy.
    Kopschina Feltes P; Doorduin J; Klein HC; Juárez-Orozco LE; Dierckx RA; Moriguchi-Jeckel CM; de Vries EF
    J Psychopharmacol; 2017 Sep; 31(9):1149-1165. PubMed ID: 28653857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of BDNF in major depressive disorder, related clinical features, and antidepressant treatment: Insight from meta-analyses.
    Cavaleri D; Moretti F; Bartoccetti A; Mauro S; Crocamo C; Carrà G; Bartoli F
    Neurosci Biobehav Rev; 2023 Jun; 149():105159. PubMed ID: 37019247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum chemokine levels in major depressive disorder.
    Lehto SM; Niskanen L; Herzig KH; Tolmunen T; Huotari A; Viinamäki H; Koivumaa-Honkanen H; Honkalampi K; Ruotsalainen H; Hintikka J
    Psychoneuroendocrinology; 2010 Feb; 35(2):226-32. PubMed ID: 19592174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
    Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
    Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melancholic and atypical major depression--connection between cytokines, psychopathology and treatment.
    Dunjic-Kostic B; Ivkovic M; Radonjic NV; Petronijevic ND; Pantovic M; Damjanovic A; Poznanovic ST; Jovanovic A; Nikolic T; Jasovic-Gasic M
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():1-6. PubMed ID: 23200828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder.
    Hung YY; Lin CC; Kang HY; Huang TL
    Brain Behav Immun; 2017 Jan; 59():265-272. PubMed ID: 27640899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets.
    Kouba BR; de Araujo Borba L; Borges de Souza P; Gil-Mohapel J; Rodrigues ALS
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.